Authored By: Sarah
11 Jul 2024

 Bipolar Disorder Therapeutics Market to grow by USD 787.02 million between 2024-2028

According to a research report “ Bipolar Disorder Therapeutics Market” by Drug Class (Antipsychotics, Mood stabilizers, Antidepressants, Others) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 787.02 million at a CAGR of  2.68% during the forecast period. The bipolar disorder therapeutics market experiences significant growth due to the increasing prevalence of bipolar disorder, driven by reduced stigma, enhanced diagnostic capabilities, and evolving societal trends. Approximately 3 million individuals worldwide were diagnosed with bipolar disorder in 2023, and this number is projected to increase during the forecast period. This market expansion can be attributed to the rising demand for effective treatment solutions for this condition..

Browse market data tables, figures, and in-depth TOC on “Bipolar Disorder Therapeutics Market” by Drug Class (Antipsychotics, Mood stabilizers, Antidepressants, Others) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Drug Class, the Antipsychotics segment is projected to dominate the market size in 2024.

In the bipolar disorder therapeutics market, hospital pharmacies play a pivotal role in the distribution chain. These establishments offer significant advantages to patients, including the ability to serve both inpatient and outpatient populations, expert advice from pharmacists, and expedited access to a vast inventory of pharmaceuticals. Hospital pharmacies are particularly valuable in stocking specialized medications, such as mood stabilizers and antipsychotics, which are crucial for managing bipolar disorder. Notable drugs like Lamotrigine (Lamictal), Valproic acid (Depakote), and Lithium are frequently available at hospital pharmacies for mood stabilization purposes.

By Distribution Channel, Hospital pharmacies  segment is expected to hold the largest market size for the year 2024.

The antipsychotic drug class segment holds a prominent position in the bipolar disorder therapeutics market, accounting for a substantial revenue share. This drug class is widely utilized to address symptoms such as mood swings, delusions, and hallucinations associated with bipolar disorder. Antipsychotic medications, including Seroquel, Olanzapine, and Aripiprazole, have proven effective in regulating mood and mitigating the severity of manic or depressive episodes. These drugs are frequently incorporated into comprehensive treatment plans and often used in conjunction with mood stabilizers. The efficacy of antipsychotics in managing bipolar disorders has solidified their status as a key solution in the global therapeutics market.

North America is forecasted to hold the largest market size by region in 2024.

The North American market holds the largest share in the bipolar disorder therapeutics industry, driven by a robust healthcare system, high prevalence of bipolar disorder cases, and increasing public awareness of mental health issues. Key players, including Pfizer and Bristol-Myers Squibb, are heavily invested in research and development to address the unmet needs of patients. The region's growth is fueled by rising demand for antipsychotics, antidepressants, and mood stabilizers, facilitated by expanded insurance coverage and telemedicine services for remote consultations.

The Bipolar Disorder Therapeutics Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Gedeon Richter Plc
  • GlaxoSmithKline Plc
  • H Lundbeck AS
  • Intra-Cellular Therapies Inc.
  • Mallinckrodt Plc
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sumitomo Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The London Psychiatry Centre
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Bipolar Disorder Therapeutics Market encompasses a range of treatments for manic depression and Bipolar I disorder. These include various classes of medications such as mood stabilizers, antipsychotics, antidepressants, and anti-anxiety drugs. Mood stabilizers, like Lithium (Li) element and anticonvulsants, play a crucial role in managing the symptoms of bipolar disorder. Lithium is an essential element that acts as a mood stabilizer, while anticonvulsants like Valproic acid and Lamotrigine are also effective. Antipsychotic drugs, such as Lurasidone, Olanzapine, Aripiprazole, and Cariprazine, are used to manage the psychotic symptoms associated with bipolar disorder. Beta blockers and Tricyclic antidepressant drugs are sometimes used off-label to treat certain symptoms. Scientific organizations and medical institutions are at the forefront of researching new treatments for bipolar disorder. Government efforts aim to increase access to these treatments, particularly for women, who are disproportionally affected by this condition. Diabetes insipidus, a condition characterized by excessive urination, can be a side effect of certain medications used to treat bipolar disorder. The vasopressin hormone is used to treat diabetes insipidus in some cases. Overall, the Bipolar Disorder Therapeutics Market continues to evolve, offering new hope for those living with this complex condition.

Market Research Overview

The Bipolar Disorder Therapeutics Market encompasses a range of treatments for mental health conditions, including medications and digital health technologies. Key therapeutic classes for Bipolar Disorder include antidepressant drugs, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, mood stabilizers like lithium (Li) and valproate, and antipsychotic drugs, such as aripiprazole, olanzapine, and lurasidone. Benzodiazepines and anticonvulsants are also utilized for managing symptoms. Combination therapies, involving the use of multiple drug classes, are increasingly popular due to their efficacy in managing the complex nature of Bipolar Disorder. Side effects and disease burden are significant concerns, leading to the development of new medications with improved safety profiles and innovative delivery methods, such as parenteral and oral formulations. Public awareness and government efforts are crucial in addressing the stigma surrounding mental disorders like Bipolar Disorder. Telemedicine and mobile apps are transforming the landscape of mental health care, providing accessible and affordable treatment options for women and other populations in need. Scientific organizations and medical institutions are collaborating to advance research and develop new therapeutic approaches.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio